Moderna held further discussions with regulators and announced that the agency would accept the company’s application for approval of its flu vaccine that uses mRNA technology.
The FDA agreed to review Moderna’s experimental mRNA influenza vaccine after Moderna resubmitted its application with modifications.
The Chosun Ilbo on MSN
14.2M COVID-19 vaccines administered despite foreign substance reports
Foreign substances such as mold, hair, and silicon dioxide (silica) were found in COVID-19 vaccines, potentially introduced ...
NEXSPIKE is the third Moderna vaccine authorized in the European Union, strengthening the Company's respiratory vaccine portfolio in Europe ...
The global vaccine Contract Development and Manufacturing Organization (CDMO) market is projected to expand at a compound ...
Union Health Minister J P Nadda launched the indigenously manufactured tetanus and adult diphtheria vaccine in Kasauli. The ...
Union Health Minister JP Nadda on Saturday launched the indigenously manufactured Tetanus and Adult Diphtheria (Td) vaccine ...
In a sudden reversal, the US Food and Drug Administration has agreed to review Moderna’s experimental mRNA influenza vaccine.
US mRNA specialist Moderna today announced that the European Commission (EC) has granted marketing authorization for mNEXSPIKE (mRNA-1283), a new COVID vaccine, for active immunization to prevent ...
Researchers suggest a vaccine could replace multiple jabs every year for seasonal respiratory infections and be on hand in the event of a new pandemic.
By Nate Raymond BOSTON, Feb 13 (Reuters) - Major U.S. medical groups urged a judge on Friday to block the Trump ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results